PTIXW VS NUWE Stock Comparison
Performance
PTIXW10/100
10/100
PTIXW returned -30.00% in the last 12 months. Based on SPY's performance of -13.78%, its performance is below average giving it a score of 10 of 100.
NUWE10/100
10/100
NUWE returned -94.75% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Profit
PTIXW10/100
10/100
Out of the last 20 quarters, PTIXW has had 0 profitable quarters and has increased their profits year over year on 0 of them.
NUWE10/100
10/100
Out of the last 20 quarters, NUWE has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
PTIXW67/100
67/100
PTIXW has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.
NUWE46/100
46/100
NUWE has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
Technicals
PTIXW
"Technicals" not found for PTIXW
NUWE25/100
25/100
NUWE receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
Earnings
PTIXW
"Earnings" not found for PTIXW
NUWE10/100
10/100
NUWE has missed earnings 8 times in the last 20 quarters.
All score calculations are broken down here to help you make more informed investing decisions
Protagenic Therapeutics, Inc. Warrant Summary
Nasdaq / PTIXW
Healthcare
Biotechnology
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Nuwellis, Inc. Common Stock Summary
Nasdaq / NUWE
Healthcare
Medical - Devices
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PTIXW to other companies in the same or a similar industry.